Skip to main content

Advertisement

SpringerLink
Log in

Symptom scores: Mumbo jumbo or meaningful measures?

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Instruments designed to assess the severity of lower urinary tract symptoms have become a routine component of the diagnostic evaluation of men with benign prostatic hyperplasia (BPH). Several validated tools have been developed to this end, including the International Prostate Symptom Score, which is used most commonly today. Despite attempts to correlate symptom score severity with commonly measured objective parameters of BPH, no clear relationships have been found. The reason for this is likely multifactorial and suggests a complex relationship among subjective and objective variables. However, symptom scores show a good correlation with the patient’s perception of quality of life and degree of bother. This is critical because the decision to treat should be largely based on these subjective variables. Moreover, symptom scores have been shown to represent a meaningful endpoint in assessing treatment response in clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Roehrborn CG, McConnell JD: Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. In Campbell’s Urology, edn 8. Edited by Walsh PC, Retik AB, Vaughn ED Jr, Wein AJ. Philadelphia: W.B. Saunders; 2002:1297–1330.

    Google Scholar 

  2. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474–479.

    PubMed  CAS  Google Scholar 

  3. Boyarsky S, Jones G, Paulson DF, Prout GR Jr: New look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hyperplasia. Trans Am Assoc Genitourin Surg 1976, 68:29–32.

    PubMed  CAS  Google Scholar 

  4. Madsen PO, Iversen P: A point system for selecting operative candidates. In Benign Prostatic Hyperplasia. Edited by Hinman F. New York: Springer-Verlag; 1985:763–765.

    Google Scholar 

  5. Fowler FJ Jr, Wennberg JE, Timothy RP, et al.: Symptom status and quality of life following prostatectomy. JAMA 1988, 259:3018–3022.

    Article  PubMed  Google Scholar 

  6. Hald T, Nordling J, Andersen JJ, et al.: A point-weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol 1991, 138(suppl):59.

    CAS  Google Scholar 

  7. Barry MJ, Fowler FJ Jr, O’Leary MP, et al.: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992, 148:1549–1557.

    PubMed  CAS  Google Scholar 

  8. Cockett AT, Khoury S, Aso Y, et al.: Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia. Channel Islands, UK: Scientific Communication International Ltd.; 1993.

    Google Scholar 

  9. Peters TJ, Donovan JL, Kay HE, et al.: The International Continence Society-“BPH” Study: the bothersomeness of urinary symptoms. J Urol 1997, 157:885–889.

    Article  PubMed  CAS  Google Scholar 

  10. Barry MJ, Fowler FJ Jr, O’Leary MP, et al.: Measuring diseasespecific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care 1995, 33:145–155.

    Article  Google Scholar 

  11. Lepor H, Williford WO, Barry MJ, et al.: For the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Eng J Med 1996, 335:533–539.

    Article  CAS  Google Scholar 

  12. Barry MJ, Williford WO, Chang Y, et al.: Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association Symptom Index and Benign Prostatic Hyperplasia Impact Index is perceptible to patients J Urol 1995, 154:1770–1774.

    Article  PubMed  CAS  Google Scholar 

  13. Roehrborn C, McConnell J, Barry M, et al.: AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547. Recent AUA treatment guidelines emphasize the importance of using symptom scores in diagnosis and demonstrate their use in assessing treatment response.

    Article  Google Scholar 

  14. Barry MJ: Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001, 158(suppl 6a):25–32. This paper offers a concise review of symptom score validation and use. It also covers the topics of sexual function and quality of life related to LUTS.

    Article  Google Scholar 

  15. O’Leary MP, Barry MJ, Fowler FJ: Hard measures of subjective outcomes: validating symptom indexes in urology. J Urol 1992, 148:1546–1548.

    PubMed  CAS  Google Scholar 

  16. Wright JG, Young NL: A comparison of different indices of responsiveness. J Clin Epidemiol 1997, 50:239–246.

    Article  PubMed  CAS  Google Scholar 

  17. Barry MJ, Cockett AT, Hollgrene HL, et al.: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993, 150:351–358.

    PubMed  CAS  Google Scholar 

  18. Barry MJ, Fowler FJ, O’Leary MP, et al.: Correlation of the American Urological Association Symptom Index with the self-administered versions of the Madsen-Iversen, Boyarsky, and Maine Medical Association Program symptom indexes: Measurement Committee of the American Urological Association. J Urol 1992, 148:1558–1564.

    PubMed  CAS  Google Scholar 

  19. O’Connor RC, Bales GT, Avila D, Gerber GS: Variability of the International Prostate Symptom Score in men with lower urinary tract symptoms. Scand J Urol Nephrol 2003, 37:35–37. The authors demonstrate the degree of variability in IPSS scores given within 1 week in a group of 210 men.

    Article  PubMed  Google Scholar 

  20. Cam K, Akman Y, Cicekci B, et al.: Mode of administration of the International Prostate Symptom Score in patients with lower urinary tract symptoms: physician versus self. Prostate Cancer Prostatic Dis 2004, 7:41–44.

    Article  PubMed  CAS  Google Scholar 

  21. Hansen BJ, Flyger H, Brasso K, et al.: Validation of the selfadministered Danish Prostate Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995, 76:451–458.

    PubMed  CAS  Google Scholar 

  22. Hansen BJ, Mortensen S, Mensink HJ, et al.: Comparison of the Danish Prostatic Symptom Score with the International Prostate Symptom Score, the Madsen-Iversen, and Boyarsky symptom indexes. Br J Urol 1998, 81:36–41.

    PubMed  CAS  Google Scholar 

  23. Donovan JL, Abrams P, Peters TJ: The ICS-BPH Study: The psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996, 77:554–562.

    PubMed  CAS  Google Scholar 

  24. Donovan JL, Peters TJ, Abrams P, et al.: Scoring the short form ICSmaleSF questionnaire. J Urol 2000, 164:1948–1955. The ICSmaleSF questionnaire represents one of the more recently derived prostate symptom score forms. It may become one of the more popular instruments used in the future.

    Article  PubMed  CAS  Google Scholar 

  25. Bruskewitz RC, Iversen P, Madsen PO: Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982, 20:602–604.

    Article  PubMed  CAS  Google Scholar 

  26. Birch NC, Hurst G, Doyle PT: Serial residual volumes in men with benign prostatic hyperplasia. Br J Urol 1988, 62:571–575.

    Article  PubMed  CAS  Google Scholar 

  27. Yalla SV, Sullivan MP, Lecamwasam HS, et al.: Correlation of American Urological Association Symptom Score with obstructive and non-obstructive prostatism. J Urol 1995, 153:674–680.

    Article  PubMed  CAS  Google Scholar 

  28. Ezz el Din K, Kiemeney AL, deWildt MJ, et al.: Correlation between uroflowmetry, prostate volume, post-void residual, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996, 48:393–397.

    Article  PubMed  CAS  Google Scholar 

  29. Reynard JM, Yang Q, Donovan JL, et al.: The ICS-BPH Study: uroflowmetry, lower urinary tract symptoms, and bladder outlet obstruction. Br J Urol 1998, 82:619–623.

    PubMed  CAS  Google Scholar 

  30. Schafer W: Basic principles and clinical application of advanced analysis of bladder voiding function. Urol Clin North Am 1990, 17:553–566.

    PubMed  CAS  Google Scholar 

  31. Sciarra A, D’Eramo G, Casale P, et al.: Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia. Prostate 1998, 34:121–128.

    Article  PubMed  CAS  Google Scholar 

  32. Eckhardt MD, Ger EP, vanVenrooij GE, Boon TA: Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2001, 57:695–700.

    Article  PubMed  CAS  Google Scholar 

  33. Djavan B, Fong YK, Harik M, et al.: Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for 4 years. Urology 2004, 64:1144–1148. This recent analysis demonstrates the importance of prostate symptom scores in assessing symptom change over time and the need for treatment.

    Article  PubMed  Google Scholar 

  34. Lepor H, Williford WO, Barry MJ, et al.: The impact of medical therapy on bother due to symptoms, quality of life, and global outcome and factors predicting response: Veterans Affairs Committee Study on Benign Prostatic Hyperplasia Study Group. J Urol 1998, 160:1358–1367.

    Article  PubMed  CAS  Google Scholar 

  35. de la Rosette JJ, Alivizatos G, Madersbacher S, et al.: EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001, 40:256–263.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, University of Texas Health Sciences Center, 6431 Fannin Street, Suite 6.018, 77030, Houston, TX, USA

    John C. Hairston MD

Authors
  1. A. Christopher Stage MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John C. Hairston MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stage, A.C., Hairston, J.C. Symptom scores: Mumbo jumbo or meaningful measures?. Curr Urol Rep 6, 251–256 (2005). https://doi.org/10.1007/s11934-005-0017-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-005-0017-2

Keywords

Search

Navigation